Pathfinder Cell Therapy (PFND) 10-K/A 31 Mar 14 2012 FY Annual report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2012			Mar. 31, 2013	Jun. 30, 2012
Document and Entity Information [Abstract]	'			'	'
Entity Registrant Name	'Pathfinder Cell Therapy, Inc.			'	'
Entity Central Index Key	'0000889428			'	'
Amendment Flag	'true			'	'
Amendment Description	'			'	'
	Explanatory Note
	This Amendment No. 2 on Form 10-K/A (the “Amendment”) amends the Annual Report on Form 10-K for the fiscal year ended December 31, 2012 of Pathfinder Cell Therapy, Inc. (the “Company”, “our”, “us” or “we”) that was originally filed with the Securities and Exchange Commission on April 1, 2013.  The Amendment, which is being filed in response to comments received from the Staff of the Division of Corporation Finance of the Securities and Exchange Commission, reflects the following changes:
		·	inclusion of our financial statements for each of the years ended December 31, 2012 and 2011 and the period from inception (November 4, 2008) through December 31, 2012 by an independent registered public accounting firm; and
		·	reclassification of certain items between general and administrative expenses and research and development expenses for all periods presented.
	Except for changes related to the foregoing, the Amendment effects no other changes to our Annual Report on Form 10-K for the year ended December 31, 2012 and 2011. Changes to Item 1. Business appear under “-Research and Development” in the amounts reflected for research and development expense.  Changes to Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations appear under “-Results of Operations” in the amounts reflected for general and administrative expense and research and development expense.
Current Fiscal Year End Date	'--12-31			'	'
Document Type	'10-K			'	'
Document Period End Date	31-Dec-12			'	'
Document Fiscal Year Focus	'2012			'	'
Document Fiscal Period Focus	'FY			'	'
Entity Well-Known Seasoned Issuer	'No			'	'
Entity Voluntary Filers	'No			'	'
Entity Current Reporting Status	'Yes			'	'
Entity Filer Category	'Smaller Reporting Company			'	'
Entity Public Float	'			'	$12,664,000
Entity Common Stock, Shares Outstanding	'			667,160,870	'

Consolidated_Balance_Sheet

Consolidated Balance Sheet (USD $)	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Current assets:	'	'
Cash	$9	$196
Accounts receivable	28	54
Inventory	33	51
Prepaid expenses	78	115
Total current assets	148	416
Intangible, net of accumulated amortization	208	227
Machinery, equipment and software, less accumulated depreciation	'	1
TOTAL	356	644
Current liabilities:	'	'
Accounts payable	76	243
Accrued expenses (including related party amount of $370, and $336, respectively	630	560
Current portion of long term payable	15	5
Insurance note payable	45	74
Note payable - Clubb Capital	244	244
Convertible notes payable (including related party amount of $700 and $0, respectively	1,965	'
Total current liabilities	2,975	1,126
Long term payable - net of current portion	232	225
Commitments and other matters (Note M)	'	'
Capital deficit:	'	'
Preferred stock, $.01 par value; shares authorized - 5,000; issued and outstanding - none	'	'
Common stock, $.001 par value; shares authorized - 1,000,000 issued and outstanding - 667,162 and 667,162 at December 31, 2012 and December 31, 2011	667	667
Additional paid-in capital	11,823	11,811
Accumulated deficit	-15,341	-13,185
Total capital deficit	-2,851	-707
TOTAL	$356	$644

Consolidated_Balance_Sheet_Par

Consolidated Balance Sheet (Parenthetical) (USD $)	Dec. 31, 2012	Dec. 31, 2011
In Thousands, except Share data, unless otherwise specified
Balance Sheet [Abstract]	'	'
Related party amount of accrued expenses	$370	$336
Related party of convertible notes payable	$700	$0
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	1,000,000	1,000,000
Common stock, shares issued	667,162	667,162
Common stock, shares outstanding	667,162	667,162

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		50 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Revenue	'	'	'
Product sales	$114	$73	$187
Revenue	114	73	187
Cost of goods sold	50	26	76
Gross profit	64	47	111
Operating expenses:	'	'	'
Research and development	1,084	1,403	3,444
General and administrative	1,015	2,232	3,708
Sales and marketing	25	30	55
Goodwill impairment loss	'	8,127	8,127
Operating expenses	2,124	11,792	15,334
Loss from operations before other income / (expense)	-2,060	-11,745	-15,223
Other income/(expense):	'	'	'
Interest expense, net	-96	-108	-242
Reversal for allowance of notes receivable from SyntheMed, Inc.	'	459	'
Reversal of a liability	'	124	124
Other income/(expense)	-96	475	-118
Net loss	($2,156)	($11,270)	($15,341)
Net loss per common share-basic and diluted	$0	($0.02)	'
Weighted average shares outstanding	667,162	526,105	'

Consolidated_Statements_of_Cha

Consolidated Statements of Changes In Stockholders Equity (USD $)	Total	Common Stock	Additional Paid In Capital	Accumulated Loss
In Thousands, except Share data
Beginning Balance, shares at Nov. 04, 2008	'	'	'	'
Cash Contributions*	$0	$332	($332)	'
Cash Contributions*, shares	'	332,050	'	'
Net Loss for Period	-32	'	'	-32
Balance at Dec. 31, 2008	-32	332	-332	-32
Balance, shares at Dec. 31, 2008	'	332,050	'	'
Cash Contributions*	430	'	430	'
Equity Issued for License*	11	126	-115	'
Equity Issued for License*, shares	'	125,950	'	'
Net Loss for Period	-547	'	'	-547
Balance at Dec. 31, 2009	-138	458	-17	-579
Balance, shares at Dec. 31, 2009	'	458,000	'	'
Cash Contributions*	307	'	307	'
Net Loss for Period	-1,294	'	'	-1,294
Balance at Dec. 31, 2010	-1,125	458	290	-1,873
Beginning Balance, shares at Dec. 31, 2010	'	458,000	'	'
Opening balance restatement for MGH license	-42	'	'	-42
Issuance of shares in Merger transaction - September 2, 2011	6,020	114	5,906	'
Issuance of shares in Merger transaction - September 2, 2011, shares	'	114,500	'	'
Issuance of shares in a private placement and conversion of notes payable - September 2, 2011 at $0.05 per shares, net of placement costs of $575	3,909	90	3,819	'
Issuance of shares in a private placement and conversion of notes payable - September 2, 2011 at $0.05 per shares, net of placement costs of $575, shares	'	89,662	'	'
Issuance of warrants to placement agent	237	'	237	'
Issuance of shares in settlement of Yissum liability	350	5	345	'
Issuance of shares in settlement of Yissum liability, shares	'	5,000	'	'
Shareholder contribution -3% merger fee due to MGH	687	'	687	'
Stock-based Compensation	527	'	527	'
Net Loss for Period	-11,270	'	'	-11,270
Balance at Dec. 31, 2011	-707	667	11,811	-13,185
Balance, shares at Dec. 31, 2011	'	667,162	'	'
Stock-based Compensation	12	'	12	'
Net Loss for Period	-2,156	'	'	-2,156
Balance at Dec. 31, 2012	($2,851)	$667	$11,823	($15,341)
Balance, shares at Dec. 31, 2012	'	667,162	'	'

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes In Stockholders Equity (Parenthetical) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2011
Statements Of Changes In Stockholders Equity [Abstract]	'
Stock issuance date of merger transaction and of private placement and conversion of notes payable	2-Sep-11
Issuance of shares, price per share	$0.05
Issuance of shares, placement costs	$575
Merger fee due to MGH	3.00%

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		50 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Cash flows from operating activities:	'	'	'
Net loss	($2,156)	($11,270)	($15,341)
Adjustments to reconcile net loss to Net cash used in operating activities:	'	'	'
Depreciation and amortization	20	19	71
Stock based compensation relating to options	12	527	539
Shareholder contribution -3% merger fee due to MGH	'	687	687
Goodwill impairment loss	'	8,127	8,127
Reversal for allowance of notes receivable from SyntheMed, Inc.	'	-459	'
Reversal of liability	'	-124	-124
Accretion of long term liability	17	'	17
Changes in operating assets and liabilities:	'	'	'
Decrease in accounts receivable	26	47	73
Decrease in interest receivable	'	5	'
Decrease in inventory	18	25	43
Decrease in prepaid expenses	136	58	180
(Decrease) increase in accounts payable	-167	3	73
Increase in accrued expenses	70	25	141
Net cash used in operating activities	-2,024	-2,330	-5,514
Cash flows from investing activities:	'	'	'
Acquisition of licenses	'	'	-90
Payments for notes receivable	'	-849	-1,173
Cash acquired from merger	'	14	14
Net cash used in investing activities	0	-835	-1,249
Cash flows from financing activities:	'	'	'
Net proceeds from the issuance of common stock	'	1,283	1,283
Payments of insurance note payable	-128	-62	-190
Proceeds from convertible notes payable	1,965	2,125	4,942
Contributions from Pathfinder, LLC members	'	'	737
Net cash provided by financing activities	1,837	3,346	6,772
Net (decrease) increase in cash	-187	181	9
Cash at beginning of period	196	15	'
Cash at end of period	9	196	9
Supplementary disclosure of non-cash investing and financing activities:	'	'	'
Members' equity issued for license	'	'	11
Notes receivable and payable through intermediary entity	'	'	130
Long term payable for license	'	94	177
Financing of placement agent commission through notes payable	'	244	244
Financing of insurance premiums through notes payable	99	136	235
Common stock issued in settlement of Yissum liability	'	350	350
Conversion of notes into common stock	'	3,107	3,107
Details of merger with SyntheMed:	'	'	'
Fair value of assets acquired	'	201	201
Liabilities assumed	'	2,322	2,322
Non-cash consideration	'	$6,020	$6,020

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	12 Months Ended
	Dec. 31, 2012
Statements Of Cash Flows [Abstract]	'
Percentage of merger fees due to related party	3.00%

The_Company_and_Going_Concern

The Company and Going Concern	12 Months Ended
	Dec. 31, 2012
Company and Going Concern [Abstract]	'
The Company and Going Concern:	'
	(NOTE A) - The Company and Going Concern:
	On September 2, 2011, the Company completed a business combination (the “Merger”) with Pathfinder, LLC, a Massachusetts limited liability company,  in accordance with the terms of that certain Agreement and Plan of Merger, dated as of December 22, 2010 (as subsequently amended, the “Merger Agreement”).   As a result of the Merger, the Company acquired 100% of the outstanding membership interests of Pathfinder LLC in exchange for the issuance to the former members of Pathfinder, LLC of a number of shares of the Company’s common stock equal to approximately 80% of outstanding shares after issuance.  Upon the Merger, the board of directors and officers of the Company were comprised of individuals designated by Pathfinder, LLC and the business of Pathfinder, LLC became the primary business of the Company.  The Company changed its name to Pathfinder Cell Therapy, Inc. immediately prior to the Merger. Pathfinder, LLC, the Company’s wholly-owned subsidiary following the Merger, is deemed to be the “accounting acquirer,” and the transaction has been accounted for as a reverse acquisition of the Company by Pathfinder, LLC under the purchase method of accounting for business combinations.  Accordingly, the information reflected in the accompanying consolidated financial statements for periods prior to the Merger is that of Pathfinder, LLC, which began operations on November 4, 2008.
	The Company is a development stage regenerative medicine company seeking to develop novel cell-based and related therapies for the treatment of a broad range of diseases and medical conditions characterized by organ-specific cell damage Regarding the legacy SyntheMed business, the Company’s strategy includes continuing to seek a sale, licensing transaction or other strategic transaction for the assets of the business and maintaining the business on a limited basis without significant development or investment pending any such transaction.
	The accompanying financial statements have been prepared on a going concern basis which contemplates continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business. For the period from November 4, 2008 (inception) through December 31, 2012, the Company has accumulated a deficit of $15,341,000, including a net loss of $2,156,000 and $11,270,000 for the years ended December 31, 2012 and 2011, has generated limited revenues and has experienced negative cash flows from operating activities. To date, the Company has relied on the proceeds raised by the issuance of convertible debt and equity to fund its operating requirements. As of December 31, 2012, the Company does not anticipate having sufficient cash on hand even when including the proceeds from subsequent borrowings in the aggregate of $305,000 through March 2013 (see Note M), or generating sufficient revenue from operations to meet the Company’s anticipated cash requirements based on its present plan of operations through December 31, 2013, without securing additional funds through the issuance of equity and/or debt. No assurance can be given that additional financing will be available to the Company on acceptable terms or at all.  In the absence of an additional cash infusion, the Company will be unable to continue as a going concern. The above conditions and events raise substantial doubt about the Company’s ability to continue as a going concern.  The financial statements do not include any adjustments relating to the recoverability and classification of the carrying amount of recorded assets or the amount and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2012
Summary Of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies:	'
	(NOTE B) - Summary of Significant Accounting Policies:
	[1]           Consolidation:
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Pathfinder, LLC. All inter-company accounts and transactions have been eliminated in consolidation.
	[2]           Revenue recognition policy:
	The Company recognizes revenue when the amounts become fixed and determinable, when product is shipped to customers and receipt of payment is reasonably assured. Terms of sale are “f.o.b. shipping point” with the customer covering all costs of shipment and insurance. All sales are final with no right of return except for defective product. Product sales are generated from the SyntheMed business through sales of REPEL-CV.
	[3]           Cash and cash equivalents:
	The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions and believe any amounts in excess of insurance limitations to be at minimal risk.  Cash and cash equivalents held in these accounts are insured by the Federal Deposit Insurance Corporation up to an unlimited amount through December 31, 2012 and a maximum of $250,000,thereafter.
	[4]           Accounts Receivable:
	Accounts receivable are stated at estimated net realizable value. Management evaluates the need for an allowance for doubtful accounts based on a combination of historical experience, aging analysis and information on specific accounts. In cases where management is aware of circumstances that may impair a specific customer’s ability to meet its financial obligations, management records a specific allowance against amounts due and reduces the net recognized receivable to the amount that we believe will be collected. For all other customers, the Company maintains a reserve that considers the total receivables outstanding, historical collection rates and economic trends. Account balances are written off when collection efforts have been exhausted and the potential for recovery is considered remote.
	[5]           Intangible Assets
	Intangible assets are amortized using the straight-line method over the estimated useful life of 15 years, which is based upon management’s timelines for the typical development, approval, and marketing and life cycle of pharmaceutical drug products.
	[6]           Goodwill
	Goodwill represents the excess of the value of the purchase consideration over the identifiable assets acquired in the Merger.  Goodwill is tested for impairment annually in the third quarter of each fiscal year. A more frequent evaluation is performed if indicators of impairment are present.
	[7]           Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets for indicators of possible impairment by comparison of the carrying amounts to future net undiscounted cash flows expected to be generated by such assets when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value or discounted estimates of future cash flows.
	[8]           Inventory:
	Inventory is stated at the lower of cost or market, as determined by the first-in, first-out method. The Company maintains an allowance for potentially slow moving and obsolete inventories. Management reviews on-hand inventory for potential slow moving and obsolete amounts and estimates the level of inventory reserve accordingly. The Company’s allowance for slow moving and obsolete inventories includes an allowance for out dated raw materials and on-hand finished goods inventory which is within six months of the expiration date. Inventory consisted of the following:
		December 31,
		2012		2011
	Raw materials	$	12,000	$	32,000
	Finished goods		21,000		19,000
		$	33,000	$	51,000
	The production of the Company’s inventory is outsourced to third party facilities located in Ohio, Minnesota and Prince Edward Island, Canada.
	[9]           Research and development:
	All research and development activities, including any preclinical and clinical studies and product development activities, are outsourced (see Note H).  Research and development costs, representing principally new product development and manufacturing development, are charged to expense as incurred.
	[10]         Patent costs:
	Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred.
	[11]         Use of estimates:
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, on an ongoing basis. We evaluate our estimates, including those related to uncollectible receivables, inventory valuation allowance, the useful lives of intangible assets, valuation of stock-based compensation and income taxes, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	[12]         Loss per share:
	Basic loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period.  Diluted loss per share for the years ended December 31, 2012 and 2011 excludes the effect of the potential exercise or conversion of securities which would result in the issuance of incremental shares of common stock because the effect would be anti-dilutive.
	Securities and the related potential number of shares of common stock not included in the dilution computation, are as follows:
		December 31,
		2012		2011
	Options		20,950,000		23,826,000
	Warrants		15,906,000		16,606,000
			36,856,000		40,432,000
	Basic and diluted net loss per common share for the historical financial statements was computed based on the exchange ratio of shares issued in the Merger.
	[13]         Stock-based compensation:
	The Company follows FASB ASC 718 “Compensation – Stock Compensation” which requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense over the requisite service period (generally the vesting period) in the financial statements based on their fair values. For options with graded vesting, the Company values the stock option grants and recognizes compensation expense as if each vesting portion of the award was a separate award. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount of expense recognized. In addition, the realization of tax benefits in excess of amounts recognized for financial reporting purposes will be recognized in the cash flow statement as a financing activity rather than as an operating activity.
	[14]         Income taxes:
	The Company accounts for income taxes using the asset and liability method described in FASB ASC 740-10, “Income Taxes”, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance.
	[15]         Fair value of financial instruments
	The carrying amounts of cash, accounts receivables, accounts payable, accrued expenses and notes payable approximate fair value based on their short-term maturity. The carrying value of the long term payable approximates fair value, as the interest rate used to discount the payable still approximates the Company’s current borrowing rate.
	[16]         Recent Accounting Pronouncements :
	In June 2011, the FASB issued ASU No. 2011-05, Presentation of Comprehensive Income, an amendment to FASB ASC Topic 220, “Comprehensive Income”.  The update gave companies the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements.  The amendments in the update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.  ASU 2011-05 was effective for the Company for fiscal years, and interim periods within those years, beginning after December 15, 2011.  In December 2011, the FASB issued ASU 2011-12, Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05.  This update stated that the specific requirement in ASU 2011-05 to present items that are reclassified from other comprehensive income to net income alongside their respective components of net income and other comprehensive income will be deferred.  In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income.  This update requires companies to present the effects on the line items of net income of significant reclassifications out of accumulated other comprehensive income if the amount being reclassified is required under U.S. generally accepted accounting principles to be reclassified in its entirety to net income in the same reporting period.  ASU 2013-02 is effective prospectively for the Company for fiscal years, and interim periods within those years, beginning after December 15, 2012.  The Company does not expect the adoption of the amended guidance to have a significant impact on its financial statements. The Company’s comprehensive loss is equal to its net loss for all periods presented, and, as a result, no statement of comprehensive loss has been included in the consolidated financial statements.
	[17]         Reclassification:
	Certain reclassifications have been made to prior year balances to conform to the current year’s presentation.

Note_Receivable_SyntheMed_Inc

Note Receivable - SyntheMed, Inc.	12 Months Ended
	Dec. 31, 2012
Note Receivable - Synthemed, Inc [Abstract]	'
Note Receivable - SyntheMed, Inc.	'
	(NOTE C) – Note Receivable – SyntheMed, Inc.:
	In connection with and pursuant to the Merger, all amounts loaned by Pathfinder, LLC to the Company, (formerly SyntheMed, Inc.), prior to the Merger totaling $1,343,000 were automatically forgiven. The Company reversed the allowance, including the allowance accrued in fiscal 2011 through the Merger date of $884,000, resulting in a net adjustment of $459,000, included in Other Income (Expense) in the accompanying consolidated financial statements.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2012
Intangible Assets [Abstract]	'
Intangible Assets:	'
	(NOTE D) – Intangible Assets:
	Intangible assets represent the intellectual property and other rights licensed to Pathfinder, LLC with respect to separate technologies under an agreement with each of the University of Glasgow and the Massachusetts General Hospital (“MGH”).  Intangible assets at each reporting date consisted of the following:
		December 31,
		2012			2011
	University of Glasgow	$	53,000		$	53,000
	MGH		224,000			224,000
			277,000			277,000
	Less accumulated amortization		69,000			50,000
		$	208,000		$	227,000
	The Company anticipates amortizing $19,000 per year until 2022, after which there will be an additional amortization expense through April 2023 of $5,900. The Company’s management has determined that the fair value of the licenses exceed the book value and thus no impairment is necessary at December 31, 2012. Amortization expense for the years ended December 31, 2012 and 2011 amounted to $19,000 each year.
	[1] University of Glasgow license agreement
	In March 2009, Pathfinder, LLC entered into a worldwide exclusive license for the technology relating to Pathfinder Cells (“PCs”) from the University of Glasgow, for cash payments of $42,000 and the issuance to the University of Glasgow and the founding scientists of membership units in Pathfinder, LLC valued at $11,000. In addition, the University of Glasgow will receive royalties on sales of products making use of the PCs and related technology (see Note H[1]).
	[2]           MGH license agreement
	In April 2009, Pathfinder, LLC entered into a worldwide exclusive license for a family of patents and patent applications covering related technology from the Massachusetts General Hospital for cash payments of $48,000 and future licensing fees payable through the first commercial sale date.  Under the agreement, prior to the achievement of first commercial sale, license fees are due to MGH and payable as follows:
	Year ending December 31,	Amount
	2011	$	5,000	(1	)
	2013		10,000
	2014		75,000
	2015		75,000
	2016 and each year thereafter	$	150,000
	(1) This amount remains unpaid at December 31, 2012.
	The Company has recorded an intangible asset and a corresponding long term payable for its estimated licensing fee obligations under the MGH license agreement. The amounts recorded represent the projected future license fees payable based on the Company’s estimate of the first year of commercial sale, discounted to the present value. If first commercial sale is not achieved by 2017, any additional license fees incurred under the agreement will continue to be capitalized and amortized over the remaining estimated useful life.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2012
Notes Payable [Abstract]	'
Note Payable:	'
	(NOTE E) – Note Payable:
	1]            Convertible Notes Payable:
	Since September 2010 and prior to the Merger, Pathfinder, LLC had been funding its operations as well as the operations of SyntheMed, Inc. with proceeds from investors, including Breisgau BioVentures SA, an owner of 52.5% of the outstanding membership interests of Pathfinder, LLC prior to the Merger, through the issuance of convertible notes payable.  The notes payable had an interest rate of 6% per annum, were due and payable on the earlier to occur of the first anniversary of issuance or the closing of the Merger and were convertible, at the election of the payee, into equity securities of the Company (then known as SyntheMed, Inc.) for the subscription price thereof in an offering by the Company conducted in connection with the Merger, which is referred to herein as the “Capital Raise”.
	At the initial closing of the Capital Raise, which occurred on September 2, 2011 immediately after the Merger, the payees elected to convert the entire outstanding principal, approximately $3,107,000 ($1,357,000 of which was held by Breisgau BioVentures SA), into the Company’s common stock sold in the Capital Raise (see Note F[2]). At December 31, 2012, the Company has included an accrual of approximately $96,000 for unpaid accrued interest, and such amount is included in Accrued Expenses in the accompanying consolidated balance sheet.
	During 2012, the Company borrowed from investors an aggregate amount of $1,965,000, evidenced by promissory notes bearing interest at 6% per annum.  Principal and interest are due and payable on the first anniversary of issuance.  At any time prior to completion or termination of the Capital Raise, the holder may elect to convert the principal amount of the promissory notes, and/or accrued interest thereon, into shares of the Company’s common stock at a price equal to the subscription price in the Capital Raise (See Note F[2]).
	[2]           Insurance Notes Payable:
	During 2011, the Company had a short term financing agreement covering $12,400 in aggregate premiums for product liability insurance relating to the SyntheMed business.  The financed amount was payable in four monthly installments each in the amount of $3,200 (including interest at 3.65% per annum) through December 2011.
	In September 2011, the Company entered into two short term financing agreements for directors’ and officers’ liability insurance premiums totaling $49,600 and $72,600 and payable in monthly installments including interest of $5,000 and $7,400, respectively. The monthly installments for both notes are due through July, 2012 and carry an interest rate of 3.78% and 3.25% per annum, respectively.
	In March 2012, the Company entered into a short term financing agreement covering $24,400 in aggregate premiums for product liability insurance relating to the SyntheMed business.  The financed amount is payable in monthly installments each in the amount of $2,500 (including interest at 4.52% per annum) through December 2012.
	In September 2012, the Company entered into a short term financing agreement for directors’ and officers’ liability insurance premium totaling $75,000 and payable in monthly installments including interest of $7,600. The monthly installments are due through July 2013 and carry an interest rate of 3.45% per annum.
	[3]   Note Payable – Clubb Capital Limited:
	In September 2011, the Company issued a note payable to Clubb Capital Limited in the principal amount of $244,000, representing the deferred portion of the commission to which Clubb Capital Limited was entitled in connection with the Capital Raise. The principal balance (together with accrued interest thereon at the rate of 6% per annum) became due and payable on demand at any time on or after December 30, 2011.

Capital_Transaction

Capital Transaction	12 Months Ended
	Dec. 31, 2012
Capital Transaction [Abstract]	'
Capital Transaction:	'
	(NOTE F) – Capital Transaction:
	[1]           Merger transaction:
	In connection with and pursuant to the Merger and at the date thereof, the Company issued an aggregate of 457,999,480 shares of common stock to the former members of Pathfinder, LLC in consideration for, among other things, 100% of the membership interests in Pathfinder, LLC.
	Because the former members of Pathfinder, LLC owned approximately 80% of the voting stock of the Company immediately after the transaction, Pathfinder, LLC is deemed to be the accounting “acquirer” and the transaction has been accounted for as a reverse acquisition by Pathfinder, LLC of the Company under the purchase method of accounting for business. Accordingly, the assets acquired and liabilities assumed were recorded as of the date of the Merger at their estimated fair values. The total consideration for the transaction was based on the fair market value of the outstanding common stock and outstanding options and warrants of the Company (formerly SyntheMed, Inc.) immediately prior to the Merger:
	Fair value of SyntheMed , Inc.’ s common stock		$	5,725,000
	Estimated fair value of SyntheMed stock options and stock warrants assumed			295,000
	Total Merger consideration		$	6,020,000
	The fair value of SyntheMed, Inc.’s common stock used in determining the purchase price was $0.05 per share based on the price per share of the 2011 private placement that occurred immediately after the Merger. The fair value of SyntheMed, Inc.’s stock options and stock warrants was determined using the Black-Scholes option pricing model with the following assumptions:
			September 2,
			2011
	Underlying stock price		$	0.05
	Expected stock price volatility			64.7% – 128.4	%
	Risk-free interest rates			0.2 %– 3.15	%
	Weighted average expected life		2.78 years
	Expected dividend yield			0
	Under the purchase method of accounting, the total purchase price is allocated to the acquired identifiable assets and liabilities assumed based on their estimated fair values as of the merger closing date. The excess of the purchase price over the fair value of assets acquired and liabilities assumed, if any, is allocated to goodwill. During the third quarter of fiscal 2011, the Company performed an impairment analysis for the goodwill generated by the 2011 Merger transaction and determined that the entire carrying amount was impaired by using a discounted cash flow method. As a result, the Company recorded an impairment charge of $8,127,000.
	Below is a breakdown of the assets acquired and liabilities assumed in the Merger:
	Asset Allocation		Value
	Accounts receivables		$	101,000
	Inventory			76,000
	Other assets (A)			37,000
	Liabilities assumed (B)			(2,321,000	)
	Total identifiable net liabilities			(2,107,000	)
	Goodwill			8,127,000
	Total fair value of SyntheMed assets and liabilities		$	6,020,000
		(A)	Includes cash, prepaid expenses and fixed assets
		(B)	Includes $1,343,000 notes payable to Pathfinder LLC  (see Note C)
	Acquisition costs incurred by the Company related to the Merger during the twelve months ended December 31, 2011 were approximately $800,000 and were expensed as incurred.
	The below schedule presents pro forma revenues and net loss information of the Company as if the Merger had occurred on January 1, 2011, for the following period (in millions, except per share amounts):
			Year ended
			31-Dec-11
			(Unaudited)
	Revenues		$	0.2
	Net Loss		$	(3.5	)(a)
	Basic and diluted net loss per common share		$	0.01
	Weighted average shares outstanding			662.2
	(a) Pro forma net loss excludes $8.1 million goodwill impairment charge, $0.8 million of Merger costs incurred in 2011 and $0.5 million net gain from reversal of allowance on note receivable, and includes a $0.6 million net loss related to the operations of the SyntheMed business.
	[2]          Private Placement:
	On September 2, 2011, immediately after the Merger, the Company completed the initial closing of the Capital Raise, a private placement in which it sold an aggregate of 89,661,520 shares of common stock at a price of $0.05 per share, for gross proceeds of $4,483,000.  Of the proceeds, $1,375,000 was paid in cash, and the balance was paid by conversion of Pathfinder, LLC debt held by investors in Pathfinder, LLC (see Note E[1]) as contemplated by the Merger Agreement.
	Clubb Capital Limited, of which Mr. Joerg Gruber, the Company’s Chairman, is Chairman and a director, acted as placement agent for the placement and received a commission equal to 7% of the gross proceeds, a portion of which was paid in cash and a portion of which was payable by a short-term note. (See Note E[3])  In addition, Clubb Capital Limited or its designees were granted warrants to purchase up to 6,276,306 shares of the Company’s common stock (representing 7% of the number of shares sold in the closing), exercisable at $0.055 per share and expiring September 30, 2016.  The shares were issued in reliance upon the exemption from registration set forth in Section 4(2) of the Act and/or Rule 506 of Regulation D and/or Regulation S.
	The grant date fair value of the warrants issued to Clubb Capital Limited or its designees was $237,000, using the Black-Scholes pricing on September 2, 2011. The resulting charges did not have an impact on Capital Deficit. The assumptions utilized to determine the fair values are indicated in the following table:
			Year Ended
			December 31,
			2011
	Exercise price at date of grant
	for warrants granted during the period		$	0.055
	Dividend yield			0	%
	Expected volatility			105.3	%
	Risk free interest rate			0.88	%
	Expected life		5 years
	[3]           Other capital transactions related to the Merger:
	Under the license agreement with MGH, Pathfinder, LLC was obligated in the event that it was acquired or substantially all of its assets were sold, to pay to MGH   an amount equal to 3% of the sale price received.  The Merger qualified as an acquisition of Pathfinder, LLC for purposes of this provision.  Pursuant to an understanding agreed prior to the Merger, the principal member of Pathfinder, LLC funded the obligation to MGH by accepting a reduction in the number of shares to which it otherwise was entitled in the Merger as a member of Pathfinder equal in amount to the number of shares owed to MGH and agreeing that those shares be issued instead to MGH.  The Company recognized a non-cash charge in General and Administrative expense at the time of the Merger in the amount of $687,000, representing the fair market value of the shares so acquired by MGH.
	[4]           Shareholder Right Plan:
	Effective immediately prior to the Merger, the Rights Agreement dated as of May 20, 2008 between SyntheMed and American Stock Transfer & Trust Company, as amended as of December 22, 2010, expired by its terms.  Accordingly, all preferred share purchase rights applicable under the Rights Agreement to the Company’s outstanding common stock have similarly expired.
	[5]          Warrants:
	As of December 31, 2012, the following warrants were outstanding to purchase up to 15,906,306 shares of the Company’s Common Stock:
		9,630,000		exercisable at $0.20 per share which expire on September 30, 2013
		6,276,306		exercisable at $0.055 per share which expire on September 30, 2016
		15,906,306
	[6]           Options:
	As a result of the Merger each option to purchase membership interests of Pathfinder, LLC outstanding immediately prior to the Merger was assumed by the Company and converted into an option to purchase Company common stock, the number of underlying shares and exercise price per share being adjusted to reflect the Merger exchange ratio. The options were converted into options to purchase an aggregate of 14,061,000 shares with an exercise price of $0.05 per share.
	Additionally, in connection with and as contemplated by the Merger, the Company increased the number of shares authorized for issuance under its 2006 Stock Option Plan to 25,000,000.
	At December 31, 2012, the Company has one stock-based compensation plan, the 2006 Stock Option Plan, under which the Company is authorized to issue incentive stock options and non-qualified stock options to purchase up to an aggregate of 25,000,000 shares of common stock. At December 31, 2012, options to purchase 19,969,000 shares of common stock were outstanding pursuant to the 2006 plan, including 14,061,000 options that converted with the Merger, and there were 5,031,000 options available under this plan.  The exercise price is determined by the Compensation Committee of the Board of Directors at the time of the granting of an option. Options vest over a period not greater than five years, and expire no later than ten years from the date of grant.
Additionally at December 31, 2012, options to purchase 63,000 shares of Common Stock were outstanding pursuant to the 2000 Plan, options to purchase 718,000 shares of Common Stock were outstanding pursuant to the 2001 Plan and options to purchase 200,000 shares of Common Stock issued outside of the plans are outstanding pursuant to other agreements.  These options vest over various periods and expire no later than ten years from the date of grant. Some of the outstanding options are subject to performance-based vesting.
A summary of the status of the Company’s stock options as of December 31, 2012 and 2011, and changes during the years ended on those dates is presented below:
						Weighted Average Exercise Price			Weighted Average Remaining Contractual Term
												Aggregate Intrinsic Value
		Shares
		(In Thousands)
Number of shares under option plans:
Outstanding at January 1, 2011			14,061			$	0.05		4.0 Years
Assumed at Merger consummation			8,765				0.42		2.5 Years
Granted			1,000				0.05		9.7 Years
Number of shares under option plans:
Outstanding at December 31, 2011			23,826			$	0.19		3.6 Years			$	0
Cancelled, expired or forfeited			2,876				0.53
Granted			-				-			-
Outstanding at December 31, 2012			20,950			$	0.14		3.3 Years			$	0
Exercisable at December 31, 2012			20,350			$	0.14		3.1 Years
Expected to vest after December 31, 2012			20,850			$	0.14					$	0
									3.3 Years
As of December 31, 2012, there was approximately $7,000 of unrecognized stock compensation related to unvested awards (net of estimated forfeitures) expected to be recognized over the next 21 months.
The Company granted 1,000,000 options during the year ended December 31, 2011 of which 250,000 vested immediately. For the year ended December 31, 2011, the Company recorded a charge of $14,000 in general and administrative expense for the fair value of these options. On the Merger date, the Company also has recorded a charge of $513,000 in general and administrative expense for the fair value of the options issued in 2010 by Pathfinder LLC, as these options vested upon the consummation of the Merger. There were no options granted during the year ended December 31, 2012.
The Company has recorded a charge of $12,000 in general and administrative expense for the year ended December 31 2012 for the pro-rata share of the fair value of the unvested options granted during September 2011 that vest through September 2014.
At December 31, 2012, the Company had 100,000 options outstanding which vest upon the achievement of certain performance criteria. These options have a term of 10 years from date of grant and an exercise price of $0.80.
The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options. The fair value of options at date of grant and the assumptions utilized to determine such values are indicated in the following table:
		Year Ended
		31-Dec-11
Underlying stock price at date of grant		$	0.05
Dividend yield			0	%
Expected volatility			96.7%-105.3	%
Risk free interest rate			0.88%- 2.08.	%
Expected life		10 years
The following table summarizes information for stock options outstanding at December 31, 2012 (in thousands, except per share data):
		Options Outstanding								Options Exercisable
					Weighted-Average		Weighted-Average						Weighted-Average
Range		Number			Remaining		Exercise Price			Number			Exercise Price
Exercise Prices		Outstanding			Contractual Life		Per Share			Exercisable			Per Share
$0.05 - 0.13			18,020		3.0 years		$	0.05			17,520		$	0.05
0.30 – 0.85			2,780		4.0 years			0.64			2,680			0.63
1.16			150		3.7 years			1.16			150			1.16
			20,950		3.3 years		$	0.14			20,350		$	0.14

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2012
Income Taxes [Abstract]	'
Income Taxes:	'
	(NOTE G) - Income Taxes:
	At December 31, 2012, we have approximately $38,655,000 of net operating loss carryforwards to offset future federal taxable income and approximately $560,000 of research and development tax credit carryforwards available to offset future federal income tax, subject to limitations for alternative minimum tax.  As a result of the Merger, the Company’s net operating losses and the research and development credit carryforwards will be subject to limitation, In general, the formula will be the value of the equity times the prescribed federal rate at December 31, 2012 of 2.87%.
	The Company’s net operating loss and research and development credit carryforwards expire as follows:
									Research
									and Development
		Year			Net Operating Loss				Tax Credit
		2013			$	7,413,000			$	123,000
		2018 - 2031				31,242,000				437,000
					$	38,655,000			$	560,000
	At December 31, 2012, the Company has net operating loss carryforwards for New Jersey State income tax purposes of approximately $15,128,000 which expire through 2027.
	The deferred tax asset, which amounted to $15,012,000 at December 31, 2012, has been offset by a valuation allowance against the entire benefit due to management's uncertainty regarding the future profitability of the Company and ability to utilize the benefit. The valuation allowance was decreased by $1,791,000 in 2012.
	The difference between income taxes at the statutory federal income tax rate and income taxes reported in the statements of operations are attributable to the following at December 31:
			2012				2011
	Income tax benefit at the federal statutory rate		$	(733,000	)		$	(3,832,000	)
	Impairment of non-deductible tax goodwill			-				2,763,000
	Expired net operating losses			2,386,000				1,580,000
	Change in valuation allowance			(1,791,000	)			(896,000	)
	Income from forgiveness of debt			-				(457,000	)
	Difference in reporting basis between tax and
	accounting due to the Merger transaction			-				332,000
	Expired R&D credit			267,000				-
	Stock based compensation			4,000				287,000
	Company’s obligation paid by shareholder			-				234,000
	State and local income tax, net of effect on federal taxes			(128,000	)			(101,000	)
	Other			(5,000	)			90,000
			$	0			$	0
	The deferred tax asset at December 31 consists of the following:
			2012				2011
	Net operating loss carryforward		$	14,052,000			$	15,568,000
	Research and development credit carryforward			560,000				816,000
	Other			400,000				400,000
				15,012,000				16,802,000
	Valuation allowance			(15,012,000	)			(16,802,000	)
			$	0			$	0
	Under the guidance of FASB ASC 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. As of December 31, 2012, the Company has not recorded any unrecognized tax benefits.
	The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of December 31, 2012, the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.
	By statute, tax years 2009–2012 remain open to examination by the major taxing jurisdictions to which we are subject.

Research_and_License_Agreement

Research and License Agreements	12 Months Ended
	Dec. 31, 2012
Research and License Agreements [Abstract]	'
Research and License Agreements:	'
	(NOTE H) - Research and License Agreements:
	[1]           University of Glasgow Agreements
	Pathfinder, LLC has entered into an agreement for a worldwide exclusive license for technology developed by the University of Glasgow. Under the terms of the license, Pathfinder, LLC is obligated to pay a royalty ranging from 1.5 - 3% of all sales based on the technology licensed from the University of Glasgow, up to a cumulative total of $12,000,000. The agreement terminates when the last patent expires or fifteen years from the date of the first commercial sale of a product.
	In April 2012, the parties extended the research period for an additional twelve-month period through March 2013 at a cost of approximately GBP 432,000 (approximately $700,000 based on exchange rates in effect on December 31, 2012), payable by the Company over the course of the twelve months. Under the extended agreement, the Company agreed to pay the remaining outstanding balance owed of $408,000 through March, 2013. For the year ended December 31, 2012 and 2011, the Company has incurred expense of approximately $691,000 and $474,000, respectively, under this agreement.
	[2]           MGH Agreement
	Pathfinder, LLC has entered into an agreement for a worldwide exclusive license for a family of patents covering related technology from the Massachusetts General Hospital (MGH). Under the license agreement, Pathfinder, LLC is obligated to pay a royalty ranging from 10 - 20% of all net sales of its product sales relating to the MGH licensed technology, up to a maximum amount of $15,000,000, and additional royalties of 3% of all net sales based on the technology licensed from the University of Glasgow, up to a cumulative total of $15,000,000. The agreement terminates when the last issued patent expires or is abandoned.
	[3]           Yissum Agreement
	Effective December 1, 2011, the Company’s agreement originally entered into with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”), on June 4, 1991, as amended, was effectively terminated by the exchange of mutual releases, and the Company entered into a new agreement with Yissum relating to the polymer technology that comprised the core technology of the Company prior to the Merger in September 2011 (the “Polymer Technology”).  Pursuant to and in connection with the new agreement, (i) the Company assigned to Yissum all of its right, title and interest in and to the patents and other intellectual property relating to the Polymer Technology; (ii) Yissum granted the Company a worldwide exclusive royalty-bearing license under the applicable Polymer Technology in the following fields (A) for REPEL-CV for cardiac indications (the “REPEL Field”) and (B) for thermo-responsive polymers  to be used for or in direct connection with (1) the Company’s Pathfinder Cells, (2) drugs or biologics for the prevention or treatment of cancer or (3) post surgical adhesion prevention (the “RTG Field”); (iii) the Company agreed to commence a research program relating to the Polymer Technology for which the Company agreed to pay Yissum $40,000; (iv) $150,000 in cash which the Company deposited in escrow in September 2011 in anticipation of entering into of the new agreement with Yissum was released to Yissum and the Company issued to Yissum 1,000,000 shares of its common stock; and (v) the Company exchanged broad mutual releases with Yissum in respect of any prior claims which included any claims by Yissum for accrued and unpaid royalties or other amounts owing under the old agreement.  The Company’s rights under the new agreement are not subject to payment of minimum royalties, as they were under the prior agreement.  The Company’s rights to the Polymer Technology in the RTG Field will be subject to compliance with a development plan which the Company is to provide within an agreed upon time frame and which will be subject to Yissum’s approval.
	Pursuant to the terms of the Merger, effective December 1, 2011, the Company issued to the former members of Pathfinder, LLC an additional aggregate of 4,000,000 shares of the Company’s common stock to protect against dilution associated with the 1,000,000 share issuance to Yissum described above.   The Company recorded a charge of $350,000 equal to the fair value of the 5,000,000 shares issued to the former Pathfinder, LLC members and to Yissum based on the market price of the Company’s stock on December 1, 2011.  This charge was offset by the reversal of the Yissum Agreement liability as of December 1, 2011 which amounted to $438,000 after the release of the $150,000 escrow amount, for a net gain of $88,000 which is included in Other Income (Expense) in the accompanying consolidated financial statements.
	[4]           diZerega agreement:
	The Company is party to an agreement relating to the Polymer Technology with Gere S. diZerega, M.D. whereby the Company is obligated to pay Dr. diZerega a royalty of one percent of all net sales of covered products in any and all countries. The agreement continues until the end of fifteen years from the date of the first commercial sale of such covered product in that country. The Company incurred $1,000 in royalty expense relating to this agreement for the year ended December 31, 2012.

Commitments_and_Other_Matters

Commitments and Other Matters	12 Months Ended
	Dec. 31, 2012
Commitments and Other Matters [Abstract]	'
Commitments and Other Matters:	'
	(NOTE I) - Commitments and Other Matters:
	[1]           Employment agreement:
	At December 31, 2012, the Company had an employment agreement with one individual that is scheduled to expire in September 2013, subject to automatic renewal for one-year periods. Pursuant to this agreement, in case of early termination under certain circumstances, the Company’s commitment regarding cash severance benefits aggregates $28,000 at December 31, 2012 and the Company’s salary obligation for 2013 is $110,000.
	[2]           Lease commitments:
	The Company has a one year operating lease commitment for office facilities space through June 2013. The operating lease agreement is subject to renewal in annual increments at the option of the Company.  Rent is charged to operating expense on a straight-line basis over the term of lease. Rent expense under the operating lease for the year ended December 31, 2012 was $7,200.

Related_Parties

Related Parties	12 Months Ended
	Dec. 31, 2012
Related Parties [Abstract]	'
Related Parties:	'
	(NOTE J) - Related Parties:
	Two of Pathfinder, LLC’s founding members, Dr. Richard Franklin and Mr. Joerg Gruber, have been directors of the Company (formerly SyntheMed, Inc.) since prior to entering the Merger Agreement.  Dr. Franklin, the Company’s CEO and President was SyntheMed’s sole executive officer prior to the Merger. The Company pays Dr. Franklin a monthly consulting fee of $10,000, which amount reflects a reduction, effective August, 2012, from the previous $15,000 per month consulting fee.  Mr. Gruber, the Company’s Chairman, is Chairman and a director of Clubb Capital Limited, the placement agent for the private placement (see Note F[2]).
	Between September 2010 and March 2011, Pathfinder, LLC borrowed an aggregate principal amount of $1,357,000 from Breisgau BioVentures SA, an owner of 52.5% of the outstanding membership interests of Pathfinder, LLC prior to the Merger.   Breisgau subsequently converted such principal amount into shares of the Company’s common stock in the Capital Raise. During 2012, the Company borrowed an additional principal amount of $700,000 from Breisgau BioVentures SA, all of which remained outstanding as of December 31, 2012. See Note E[1].
	The Company’s core technology was originally derived from research conducted at the University of Glasgow.  The Company relies on the University of Glasgow as well as third party laboratories for its research and development activities, all of which is funded by the Company. Intellectual property resulting from activities conducted at the University of Glasgow is owned by the university and licensed to the Company under the terms of a license agreement between the university and the Company.  The university beneficially owns 9.5% of the outstanding shares of common stock of the Company. Additionally, Dr. Paul Shiels led and Dr. Wayne Davies participated in the research conducted at the university and are co-inventors of the technology derived therefrom.  Dr. Shiels is affiliated with the university and Dr. Davies was affiliated with the university at the time of the research and has since retired from that position.  Dr. Shiels assists with the Company’s research and development program through the University of Glasgow and Dr. Davies provides scientific consulting services to the Company.  Dr. Shiels and Dr. Davies beneficially own 5.7% and 3.8%, respectively, of the outstanding shares of common stock of the Company.

Retirement_Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2012
Retirement Plan [Abstract]	'
Retirement Plan:	'
	(NOTE K) - Retirement Plan:
	The Company has a defined contribution retirement plan which was adopted by the Company (then known as SyntheMed, Inc.) in March 2007 and qualifies under section 401(k) of the Internal Revenue Code. The plan allows all employees, upon commencement of employment, to voluntarily contribute amounts not exceeding the maximum allowed under the Internal Revenue Code. The Company is obligated to make a matching contribution equal to 100% of each employee’s salary deferral contributions made at the rate of 4% of total compensation up to a maximum of $245,000. During the year ended December 31, 2012 and 2011, the Company made matching contributions to the plan in the amount of $4,400 and $1,800 respectively.

Nature_of_Business

Nature of Business	12 Months Ended
	Dec. 31, 2012
Nature Of Business [Abstract]	'
Nature of Business:	'
	(NOTE L) – Nature of Business:
	Product sales are generated from the SyntheMed business through sales of REPEL-CV.
	The following table summarizes the Company’s revenues at December 31 (in thousands):
		Years Ended December 31,
		2012		2011
		Revenues
	United States	$	13	$	7
	Brazil		17		-
	Columbia		15		-
	Italy		2		5
	Czech Republic		15		5
	Hong Kong		37		54
	Russia		15
	Other countries		-		2
		$	114	$	73
	All of the Company’s Long-Lived Assets are located in the United States of America.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2012
Subsequent Events [Abstract]	'
Subsequent Events:	'
	(NOTE M) – Subsequent Events:
	Bridge Financing
	Subsequent to December 31, 2012, the Company borrowed an additional aggregate principal amount of $305,000, of which $205,000 was from Breisgau BioVentures SA (See Note E[1]) and $100,000 from Mr. Joerg Gruber (See Note J) on the same terms as amounts borrowed during the year then ended.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2012
Summary Of Significant Accounting Policies [Abstract]	'
Consolidation:	'
	[1]           Consolidation:
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Pathfinder, LLC. All inter-company accounts and transactions have been eliminated in consolidation.
Revenue recognition policy:	'
	[2]           Revenue recognition policy:
	The Company recognizes revenue when the amounts become fixed and determinable, when product is shipped to customers and receipt of payment is reasonably assured. Terms of sale are “f.o.b. shipping point” with the customer covering all costs of shipment and insurance. All sales are final with no right of return except for defective product. Product sales are generated from the SyntheMed business through sales of REPEL-CV.
Cash and cash equivalents:	'
	[3]           Cash and cash equivalents:
	The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions and believe any amounts in excess of insurance limitations to be at minimal risk.  Cash and cash equivalents held in these accounts are insured by the Federal Deposit Insurance Corporation up to an unlimited amount through December 31, 2012 and a maximum of $250,000,thereafter.
Accounts Receivable:	'
	[4]           Accounts Receivable:
	Accounts receivable are stated at estimated net realizable value. Management evaluates the need for an allowance for doubtful accounts based on a combination of historical experience, aging analysis and information on specific accounts. In cases where management is aware of circumstances that may impair a specific customer’s ability to meet its financial obligations, management records a specific allowance against amounts due and reduces the net recognized receivable to the amount that we believe will be collected. For all other customers, the Company maintains a reserve that considers the total receivables outstanding, historical collection rates and economic trends. Account balances are written off when collection efforts have been exhausted and the potential for recovery is considered remote.
Intangible Assets	'
	[5]           Intangible Assets
	Intangible assets are amortized using the straight-line method over the estimated useful life of 15 years, which is based upon management’s timelines for the typical development, approval, and marketing and life cycle of pharmaceutical drug products.
Goodwill	'
	[6]           Goodwill
	Goodwill represents the excess of the value of the purchase consideration over the identifiable assets acquired in the Merger.  Goodwill is tested for impairment annually in the third quarter of each fiscal year. A more frequent evaluation is performed if indicators of impairment are present.
Impairment of Long-Lived Assets	'
	[7]           Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets for indicators of possible impairment by comparison of the carrying amounts to future net undiscounted cash flows expected to be generated by such assets when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value or discounted estimates of future cash flows.
Inventory:	'
	[8]           Inventory:
	Inventory is stated at the lower of cost or market, as determined by the first-in, first-out method. The Company maintains an allowance for potentially slow moving and obsolete inventories. Management reviews on-hand inventory for potential slow moving and obsolete amounts and estimates the level of inventory reserve accordingly. The Company’s allowance for slow moving and obsolete inventories includes an allowance for out dated raw materials and on-hand finished goods inventory which is within six months of the expiration date. Inventory consisted of the following:
		December 31,
		2012		2011
	Raw materials	$	12,000	$	32,000
	Finished goods		21,000		19,000
		$	33,000	$	51,000
	The production of the Company’s inventory is outsourced to third party facilities located in Ohio, Minnesota and Prince Edward Island, Canada.
Research and development:	'
	[9]           Research and development:
	All research and development activities, including any preclinical and clinical studies and product development activities, are outsourced (see Note H).  Research and development costs, representing principally new product development and manufacturing development, are charged to expense as incurred.
Patent costs:	'
	[10]         Patent costs:
	Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred.
Use of estimates:	'
	[11]         Use of estimates:
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, on an ongoing basis. We evaluate our estimates, including those related to uncollectible receivables, inventory valuation allowance, the useful lives of intangible assets, valuation of stock-based compensation and income taxes, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Loss per share:	'
	[12]         Loss per share:
	Basic loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period.  Diluted loss per share for the years ended December 31, 2012 and 2011 excludes the effect of the potential exercise or conversion of securities which would result in the issuance of incremental shares of common stock because the effect would be anti-dilutive.
	Securities and the related potential number of shares of common stock not included in the dilution computation, are as follows:
		December 31,
		2012		2011
	Options		20,950,000		23,826,000
	Warrants		15,906,000		16,606,000
			36,856,000		40,432,000
	Basic and diluted net loss per common share for the historical financial statements was computed based on the exchange ratio of shares issued in the Merger.
Stock-based compensation:	'
	[13]         Stock-based compensation:
	The Company follows FASB ASC 718 “Compensation – Stock Compensation” which requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense over the requisite service period (generally the vesting period) in the financial statements based on their fair values. For options with graded vesting, the Company values the stock option grants and recognizes compensation expense as if each vesting portion of the award was a separate award. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount of expense recognized. In addition, the realization of tax benefits in excess of amounts recognized for financial reporting purposes will be recognized in the cash flow statement as a financing activity rather than as an operating activity.
Income taxes:	'
	[14]         Income taxes:
	The Company accounts for income taxes using the asset and liability method described in FASB ASC 740-10, “Income Taxes”, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance.
Fair value of financial instruments	'
	[15]         Fair value of financial instruments
	The carrying amounts of cash, accounts receivables, accounts payable, accrued expenses and notes payable approximate fair value based on their short-term maturity. The carrying value of the long term payable approximates fair value, as the interest rate used to discount the payable still approximates the Company’s current borrowing rate.
Recent accounting pronouncements	'
	[16]         Recent Accounting Pronouncements :
	In June 2011, the FASB issued ASU No. 2011-05, Presentation of Comprehensive Income, an amendment to FASB ASC Topic 220, “Comprehensive Income”.  The update gave companies the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements.  The amendments in the update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.  ASU 2011-05 was effective for the Company for fiscal years, and interim periods within those years, beginning after December 15, 2011.  In December 2011, the FASB issued ASU 2011-12, Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05.  This update stated that the specific requirement in ASU 2011-05 to present items that are reclassified from other comprehensive income to net income alongside their respective components of net income and other comprehensive income will be deferred.  In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income.  This update requires companies to present the effects on the line items of net income of significant reclassifications out of accumulated other comprehensive income if the amount being reclassified is required under U.S. generally accepted accounting principles to be reclassified in its entirety to net income in the same reporting period.  ASU 2013-02 is effective prospectively for the Company for fiscal years, and interim periods within those years, beginning after December 15, 2012.  The Company does not expect the adoption of the amended guidance to have a significant impact on its financial statements. The Company’s comprehensive loss is equal to its net loss for all periods presented, and, as a result, no statement of comprehensive loss has been included in the consolidated financial statements.
Reclassification:	'
	[17]         Reclassification:
	Certain reclassifications have been made to prior year balances to conform to the current year’s presentation.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2012
Summary Of Significant Accounting Policies [Abstract]	'
Summary of Inventory	'
		December 31,
		2012		2011
	Raw materials	$	12,000	$	32,000
	Finished goods		21,000		19,000
		$	33,000	$	51,000
Summary of securities and related potential Anti diluted common stock	'
		December 31,
		2012		2011
	Options		20,950,000		23,826,000
	Warrants		15,906,000		16,606,000
			36,856,000		40,432,000

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2012
Intangible Assets [Abstract]	'
Summary of intangible assets	'
		December 31,
		2012			2011
	University of Glasgow	$	53,000		$	53,000
	MGH		224,000			224,000
			277,000			277,000
	Less accumulated amortization		69,000			50,000
		$	208,000		$	227,000
Summary of license fees due and payable to MGH	'
	Year ending December 31,	Amount
	2011	$	5,000	(1	)
	2013		10,000
	2014		75,000
	2015		75,000
	2016 and each year thereafter	$	150,000

Capital_Transaction_Tables

Capital Transaction (Tables)	12 Months Ended
	Dec. 31, 2012
Capital Transaction [Abstract]	'
Business combination, Merger consideration	'
	Fair value of SyntheMed , Inc.’ s common stock		$	5,725,000
	Estimated fair value of SyntheMed stock options and stock warrants assumed			295,000
	Total Merger consideration		$	6,020,000
Assumptions used to calculate fair stock options and stock warrants	'
			September 2,
			2011
	Underlying stock price		$	0.05
	Expected stock price volatility			64.7% – 128.4	%
	Risk-free interest rates			0.2 %– 3.15	%
	Weighted average expected life		2.78 years
	Expected dividend yield			0
Summary of breakdown of the assets acquired and liabilities assumed	'
	Asset Allocation		Value
	Accounts receivables		$	101,000
	Inventory			76,000
	Other assets (A)			37,000
	Liabilities assumed (B)			(2,321,000	)
	Total identifiable net liabilities			(2,107,000	)
	Goodwill			8,127,000
	Total fair value of SyntheMed assets and liabilities		$	6,020,000
		(A)	Includes cash, prepaid expenses and fixed assets
		(B)	Includes $1,343,000 notes payable to Pathfinder LLC  (see Note C)
Pro forma revenues and earnings information of the Company	'
			Year ended
			31-Dec-11
			(Unaudited)
	Revenues		$	0.2
	Net Loss		$	(3.5	)(a)
	Basic and diluted net loss per common share		$	0.01
	Weighted average shares outstanding			662.2
	(a) Pro forma net loss excludes $8.1 million goodwill impairment charge, $0.8 million of Merger costs incurred in 2011 and $0.5 million net gain from reversal of allowance on note receivable, and includes a $0.6 million net loss related to the operations of the SyntheMed business.
Summary of warrants	'
		9,630,000		exercisable at $0.20 per share which expire on September 30, 2013
		6,276,306		exercisable at $0.055 per share which expire on September 30, 2016
		15,906,306
Summary of stock options activity	'
							Weighted Average Exercise Price			Weighted Average Remaining Contractual Term
													Aggregate Intrinsic Value
			Shares
			(In Thousands)
	Number of shares under option plans:
	Outstanding at January 1, 2011			14,061			$	0.05		4.0 Years
	Assumed at Merger consummation			8,765				0.42		2.5 Years
	Granted			1,000				0.05		9.7 Years
	Number of shares under option plans:
	Outstanding at December 31, 2011			23,826			$	0.19		3.6 Years			$	0
	Cancelled, expired or forfeited			2,876				0.53
	Granted			-				-			-
	Outstanding at December 31, 2012			20,950			$	0.14		3.3 Years			$	0
	Exercisable at December 31, 2012			20,350			$	0.14		3.1 Years
	Expected to vest after December 31, 2012			20,850			$	0.14					$	0
										3.3 Years
Summary of information for stock options outstanding	'
			Options Outstanding								Options Exercisable
						Weighted-Average		Weighted-Average						Weighted-Average
	Range		Number			Remaining		Exercise Price			Number			Exercise Price
	Exercise Prices		Outstanding			Contractual Life		Per Share			Exercisable			Per Share
	$0.05 - 0.13			18,020		3.0 years		$	0.05			17,520		$	0.05
	0.30 – 0.85			2,780		4.0 years			0.64			2,680			0.63
	1.16			150		3.7 years			1.16			150			1.16
				20,950		3.3 years		$	0.14			20,350		$	0.14
Stock Option [Member]	'
Subsidiary, Sale of Stock [Line Items]	'
Summary of grant date fair value of warrants and options	'
			Year Ended
			31-Dec-11
	Underlying stock price at date of grant		$	0.05
	Dividend yield			0	%
	Expected volatility			96.7%-105.3	%
	Risk free interest rate			0.88%- 2.08.	%
	Expected life		10 years
Warrant [Member]	'
Subsidiary, Sale of Stock [Line Items]	'
Summary of grant date fair value of warrants and options	'
			Year Ended
			December 31,
			2011
	Exercise price at date of grant
	for warrants granted during the period		$	0.055
	Dividend yield			0	%
	Expected volatility			105.3	%
	Risk free interest rate			0.88	%
	Expected life		5 years

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2012
Income Taxes [Abstract]	'
Summary of net operating loss and research and development credit carryforwards expire	'
									Research
									and Development
		Year			Net Operating Loss				Tax Credit
		2013			$	7,413,000			$	123,000
		2018 - 2031				31,242,000				437,000
					$	38,655,000			$	560,000
Summary of difference between income taxes at statutory federal income tax rate	'
			2012				2011
	Income tax benefit at the federal statutory rate		$	(733,000	)		$	(3,832,000	)
	Impairment of non-deductible tax goodwill			-				2,763,000
	Expired net operating losses			2,386,000				1,580,000
	Change in valuation allowance			(1,791,000	)			(896,000	)
	Income from forgiveness of debt			-				(457,000	)
	Difference in reporting basis between tax and
	accounting due to the Merger transaction			-				332,000
	Expired R&D credit			267,000				-
	Stock based compensation			4,000				287,000
	Company’s obligation paid by shareholder			-				234,000
	State and local income tax, net of effect on federal taxes			(128,000	)			(101,000	)
	Other			(5,000	)			90,000
			$	0			$	0
Summary of deferred tax asset	'
			2012				2011
	Net operating loss carryforward		$	14,052,000			$	15,568,000
	Research and development credit carryforward			560,000				816,000
	Other			400,000				400,000
				15,012,000				16,802,000
	Valuation allowance			(15,012,000	)			(16,802,000	)
			$	0			$	0

Nature_of_Business_Tables

Nature of Business (Tables)	12 Months Ended
	Dec. 31, 2012
Nature Of Business [Abstract]	'
Summary of company's revenues	'
		Years Ended December 31,
		2012		2011
		Revenues
	United States	$	13	$	7
	Brazil		17		-
	Columbia		15		-
	Italy		2		5
	Czech Republic		15		5
	Hong Kong		37		54
	Russia		15
	Other countries		-		2
		$	114	$	73

The_Company_and_Going_Concern_

The Company and Going Concern (Details) (USD $)	2 Months Ended	12 Months Ended				50 Months Ended
	Dec. 31, 2008	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2012	Sep. 02, 2011
Company and Going Concern (Textual)	'	'	'	'	'	'	'
Acquired outstanding membership interests (in percentage)	'	100.00%	'	'	'	100.00%	100.00%
Exchange of issuance common stock to former members (in percentage)	'	80.00%	'	'	'	80.00%	80.00%
Net loss	($32,000)	($2,156,000)	($11,270,000)	($1,294,000)	($547,000)	($15,341,000)	'
Aggregate borrowed amount	'	305,000	'	'	'	305,000	'
Accumulated deficit	'	($15,341,000)	($13,185,000)	'	'	($15,341,000)	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Inventory	'	'
Raw materials	$12,000	$32,000
Finished goods	21,000	19,000
Total inventories	$33,000	$51,000

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Antidilutive securities excluded from computation of earning per share	'	'
Antidilutive common shares	36,856,000	40,432,000
Stock Options [Member]	'	'
Antidilutive securities excluded from computation of earning per share	'	'
Antidilutive common shares	20,950,000	23,826,000
Warrant [Member]	'	'
Antidilutive securities excluded from computation of earning per share	'	'
Antidilutive common shares	15,906,000	16,606,000

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
Summary Of Significant Accounting Policies (Textual)	'
Cash and cash equivalents insured through December 31, 2012	$250,000
Useful life of intangible assets	'15 years

Note_Receivable_SyntheMed_Inc_

Note Receivable - SyntheMed, Inc. (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Note Receivable - SyntheMed, Inc. (Textual)	'
Notes receivable	$1,343,000
Principal balance, reserve	884,000
Net adjustment included in Other Income (Expense)	$459,000

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Summary of intangible assets	'	'
Intangible assets	$277,000	$277,000
Less accumulated amortization	69,000	50,000
Total intangible assets	208,000	227,000
University of Glasgow [Member]	'	'
Summary of intangible assets	'	'
Intangible assets	53,000	53,000
Massachusetts General Hospital (MGH) [Member]	'	'
Summary of intangible assets	'	'
Intangible assets	$224,000	$224,000

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Dec. 31, 2012
Summary of license fees due and payable	'
2011	$5,000
2013	10,000
2014	75,000
2015	75,000
2016 and each year thereafter	$150,000

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2009	Apr. 30, 2009
			University of Glasgow [Member]	Massachusetts General Hospital (MGH) [Member]
Intangible Assets (Textual)	'	'	'	'
Payment for license	'	'	$42,000	$48,000
Value of membership unit in LLC	'	'	11,000	'
Amortization expense	19,000	19,000	'	'
Remaining amortization period for intangible assets	'Company anticipates amortizing $19,000 per year until 2022, after which there will be an additional amortization expense through April 2023 of $5,900.	'	'	'
Additional amortization expenses	$5,900	'	'	'

Notes_Payable_Details

Notes Payable (Details) (USD $)

12 Months Ended

50 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Sep. 30, 2011

Sep. 30, 2010

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Sep. 30, 2010

Dec. 31, 2012

Sep. 30, 2011

Dec. 31, 2012

Sep. 30, 2011

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2012

Sep. 30, 2011

Breisgau BioVentures SA [Member]

Breisgau BioVentures SA [Member]

Product liability insurance [Member]

Product liability insurance [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Promissory Notes [Member]

Financing agreement one [Member]

Financing agreement one [Member]

Financing agreement two [Member]

Financing agreement two [Member]

Financing agreement two [Member]

Financing agreement three [Member]

Note Payable [Member]

Installment

Directors' and officers' liability insurance premiums [Member]

Directors' and officers' liability insurance premiums [Member]

Directors' and officers' liability insurance premiums [Member]

Directors' and officers' liability insurance premiums [Member]

Directors' and officers' liability insurance premiums [Member]

Directors' and officers' liability insurance premiums [Member]

Notes Payable (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment ownership percentage by investor

'

'

'

'

52.50%

'

'

'

'

'

'

'

'

'

'

'

'

Interest Rate on notes

'

'

'

'

6.00%

4.52%

3.65%

'

6.00%

6.00%

3.78%

'

3.25%

'

'

3.45%

6.00%

Aggregate borrowed amount

$305,000

'

$305,000

'

'

'

'

'

'

$1,965,000

'

'

'

'

'

'

'

Conversion of notes into common stock

'

3,107,000

3,107,000

1,357,000

'

'

'

3,107,000

'

'

'

'

'

'

'

'

'

Issuance of additional borrowing

'

2,125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

244,000

Notes, monthly installment paid

'

'

'

'

'

2,500

3,200

'

'

'

'

'

'

'

'

7,600

'

Number of monthly installments

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

Short term financing agreement amount covering premiums for product liability insurance

'

'

'

'

'

24,400

12,400

'

'

'

49,600

'

72,600

'

'

75,000

'

Notes, monthly installments paid, interest

'

'

'

'

'

'

'

'

'

'

5,000

'

7,400

'

'

'

'

Unpaid accrual Interest

$96,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Monthly installments due period

'

'

'

'

'

'

'

'

'

'

'

'July, 2013.

'

'July, 2012

'July, 2012

'

'

Capital_Transaction_Details

Capital Transaction (Details) (SyntheMed, Inc. [Member], USD $)	50 Months Ended
	Dec. 31, 2012
Business combination, Merger consideration	'
Total Merger consideration	$6,020,000
Common Stock [Member]	'
Business combination, Merger consideration	'
Total Merger consideration	5,725,000
Stock options and stock warrants assumed [Member]	'
Business combination, Merger consideration	'
Total Merger consideration	$295,000

Capital_Transaction_Details_1

Capital Transaction (Details 1) (SyntheMed, Inc. [Member], USD $)	1 Months Ended
	Sep. 02, 2011
SyntheMed, Inc. [Member]	'
Assumptions used to calculate fair stock options and stock warrants	'
Underlying stock price	$0.05
Expected stock price volatility, minimum	64.70%
Expected stock price volatility, maximum	128.40%
Risk-free interest rates, minimum	0.20%
Risk-free interest rates, maximum	3.15%
Weighted average expected life	'2 years 9 months 11 days
Expected dividend yield	0.00%

Capital_Transaction_Details_2

Capital Transaction (Details 2) (USD $)	Dec. 31, 2012
Breakdown of assets acquired and liabilities assumed in Merger	'
Accounts receivables	$101,000
Inventory	76,000
Other assets (A)	37,000
Liabilities assumed (B)	-2,321,000
Total identifiable net liabilities	-2,107,000
Goodwill	8,127,000
Total fair value of SyntheMed assets and liabilities	$6,020,000

Capital_Transaction_Details_3

Capital Transaction (Details 3) (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2011
Business Acquisition, Pro Forma Information [Abstract]	'
Revenues	$0.20
Net loss	($3.50)
Basic and diluted net loss per common share	$0.01
Weighted average shares outstanding	662.2

Capital_Transaction_Details_4

Capital Transaction (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
		Private Placement [Member]
Assumptions used to calculate fair stock options and stock warrants	'	'
Exercise price of warrants	$0.06	$0.06
Expected dividend yield	'	0.00%
Expected volatility	'	105.30%
Risk free interest rate	'	0.88%
Weighted average expected life	'	'5 years

Capital_Transaction_Details_5

Capital Transaction (Details 5)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Summary of warrants	'	'	'
Outstanding , Options	20,950	23,826	14,061
Warrant [Member]	'	'	'
Summary of warrants	'	'	'
Outstanding , Options	15,906,306	'	'
Expire on September 30, 2013 [Member] | Warrant [Member]	'	'	'
Summary of warrants	'	'	'
Outstanding , Options	9,630,000	'	'
Expire on September 30, 2016 [Member] | Warrant [Member]	'	'	'
Summary of warrants	'	'	'
Outstanding , Options	6,276,306	'	'

Capital_Transaction_Details_6

Capital Transaction (Details 6) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Summary of stock options activity	'	'
Outstanding at Beginning, Shares	23,826	14,061
Outstanding at Beginning, Weighted Average Exercise Price	$0.19	$0.05
Outstanding at Beginning, Weighted Average Remaining Contractual Term	'3 years 3 months 18 days	'4 years
Cancelled, expired or forfeited, Shares	2,876	'
Cancelled, expired or forfeited, Weighted Average Exercise Price	$0.53	'
Assumed at Merger consummation, shares	'	8,765
Assumed at Merger consummation, Weighted Average Exercise Price	'	$0.42
Assumed at Merger consummation, Weighted Average Remaining Contractual Term	'	'2 years 6 months
Granted, Shares	1,000	'
Granted, Weighted Average Exercise Price	'	$0.05
Granted, Weighted Average Remaining Contractual Term	'0 years	'9 years 8 months 12 days
Outstanding at Ending, Shares	20,950	23,826
Outstanding at Ending, Weighted Average Exercise Price	$0.14	$0.19
Outstanding at Ending, Weighted Average Remaining Contractual Term	'3 years 3 months 18 days	'3 years 7 months 6 days
Outstanding at Ending, Aggregate Intrinsic Value	$0	$0
Exercisable at December 31, 2012, Shares	20,350	'
Exercisable at December 31, 2012, Weighted Average Exercise Price	$0.14	'
Exercisable at December 31, 2012, Weighted Average Remaining Contractual Term	'3 years 1 month 6 days	'
Expected to vest after December 31, 2012, Shares	20,850	250,000
Expected to vest after December 31, 2012, Weighted Average Exercise Price	$0.14	'
Expected to vest after December 31, 2012, Weighted Average Remaining Contractual Term	'3 years 3 months 18 days	'
Expected to vest after December 31, 2012, Aggregate Intrinsic Value	$0	'

Capital_Transaction_Details_7

Capital Transaction (Details 7) (Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2012
Stock Option [Member]	'
Assumptions used to calculate fair stock options and stock warrants	'
Underlying stock price	$0.05
Expected dividend yield	0.00%
Expected stock price volatility, minimum	96.70%
Expected stock price volatility, maximum	105.30%
Risk-free interest rates, minimum	0.88%
Risk-free interest rates, maximum	2.08%
Weighted average expected life	'10 years

Capital_Transaction_Details_8

Capital Transaction (Details 8) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Summary stock option	'	'	'
Outstanding , Options	20,950	23,826	14,061
Weighted-Average Remaining Contractual Life, Outstanding	'3 years 3 months 18 days	'4 years	'
Weighted-Average Exercise Price Per Share, Outstanding	$0.14	$0.19	$0.05
Options Exercisable	20,350	'	'
Weighted-Average Exercise Price Per Share, Exercisable	$0.14	'	'
Range One [Member]	'	'	'
Summary stock option	'	'	'
Exercise Prices Range, Minimum	$0.05	'	'
Exercise Prices Range, Maximum	$0.13	'	'
Outstanding , Options	18,020	'	'
Weighted-Average Remaining Contractual Life, Outstanding	'3 years	'	'
Weighted-Average Exercise Price Per Share, Outstanding	$0.05	'	'
Options Exercisable	17,520	'	'
Weighted-Average Exercise Price Per Share, Exercisable	$0.05	'	'
Range Two [Member]	'	'	'
Summary stock option	'	'	'
Exercise Prices Range, Minimum	$0.30	'	'
Exercise Prices Range, Maximum	$0.85	'	'
Outstanding , Options	2,780	'	'
Weighted-Average Remaining Contractual Life, Outstanding	'4 years	'	'
Weighted-Average Exercise Price Per Share, Outstanding	$0.64	'	'
Options Exercisable	2,680	'	'
Weighted-Average Exercise Price Per Share, Exercisable	$0.63	'	'
Range Three [Member]	'	'	'
Summary stock option	'	'	'
Exercise Prices Range	$1.16	'	'
Outstanding , Options	150	'	'
Weighted-Average Remaining Contractual Life, Outstanding	'3 years 8 months 12 days	'	'
Weighted-Average Exercise Price Per Share, Outstanding	$1.16	'	'
Options Exercisable	150	'	'
Weighted-Average Exercise Price Per Share, Exercisable	$1.16	'	'

Capital_Transaction_Details_Te

Capital Transaction (Details Textual) (USD $)	1 Months Ended	12 Months Ended		50 Months Ended
	Sep. 30, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Sep. 02, 2011	Dec. 31, 2010
Capital Transaction (Textual)	'	'	'	'	'	'
Common stock, shares authorized	'	1,000,000	1,000,000	1,000,000	'	'
Common stock, shares outstanding	'	667,162	667,162	667,162	'	'
Options converted with merger	'	1,000	'	'	'	'
Options outstanding under stock option plan	'	20,950	23,826	20,950	'	14,061
Shares issued to the former members	'	457,999,480	'	457,999,480	'	'
Percentage of membership interests in acquired company	'	100.00%	'	100.00%	100.00%	'
Exchange of issuance common stock to former members (in percentage)	'	80.00%	'	80.00%	80.00%	'
Purchase price of shares of acquired company, per share	'	$0.05	'	$0.05	'	'
Impairment charge related to goodwill	'	'	$8,127,000	$8,127,000	'	'
Notes payables	'	1,343,000	'	1,343,000	'	'
Acquisition costs incurred	'	'	800,000	'	'	'
Amount of goodwill impairment excluded in pro forma net loss	'	'	8,100,000	'	'	'
Merger related costs excluded from proforma net loss	'	'	800,000	'	'	'
Net gain (loss) from reversal of allowance	'	'	500,000	'	'	'
Amount of net loss excluded from proforma net loss related to the operations of the SyntheMed business	'	'	600,000	'	'	'
Issuance of common stock through private placement	'	'	'	'	89,661,520	'
Price of common stock per share	'	'	'	'	$0.05	'
Proceeds from private placement	4,483,000	'	'	'	'	'
Cash paid in private placement	'	'	'	'	1,375,000	'
Percentage of gross proceeds paid to placement agent	'	7.00%	'	7.00%	'	'
Number of shares of acquired company purchased by issuance of warrants	'	6,276,306	'	6,276,306	'	'
Percentage of shares of acquired company purchased by issuance of warrants	'	7.00%	'	7.00%	'	'
Exercise price of warrants	'	$0.06	'	'	'	'
Fair value of warrant issued	237,000	'	'	'	'	'
Percentage of sale price of acquired company paid to MGH, Pathfinder, LLC	'	3.00%	'	3.00%	'	'
Non-cash charge in general and administrative expenses	'	687,000	'	687,000	'	'
Unrecognized stock compensation related to unvested awards	'	7,000	'	7,000	'	'
Expected period in which compensation cost recognized	'	'21 months	'	'	'	'
Charge recorded in general and administrative expense	'	12,000	14,000	'	'	'
Stock option vested upon achievement of certain performance criteria	'	25,000,000	'	25,000,000	'	'
Fair value of option recorded in general and administrative expense	'	'	$513,000	'	'	'
Term of options	'	'10 years	'	'	'	'
Exercise price of options	'	$0.80	$0.05	$0.80	'	'
Number of shares purchasable by warrants outstanding	'	15,906,306	3,280,000	15,906,306	'	'
Converted options	'	14,061,000	'	'	'	'
Common stock issued outside option plan which remain outstanding to other agreement	'	'	200,000	'	'	'
Option vested	'	20,850	250,000	20,850	'	'
Options outstanding vested upon achievement	'	100,000	'	'	'	'
Expire on September 30, 2012 [Member]	'	'	'	'	'	'
Capital Transaction (Textual)	'	'	'	'	'	'
Exercise price of warrants having certain expiration period	'	'	$0.50	'	'	'
Expire on September 30, 2013 [Member]	'	'	'	'	'	'
Capital Transaction (Textual)	'	'	'	'	'	'
Exercise price of warrants having certain expiration period	'	'	$0.20	'	'	'
Expire on September 30, 2016 [Member]	'	'	'	'	'	'
Capital Transaction (Textual)	'	'	'	'	'	'
Exercise price of warrants having certain expiration period	'	'	$0.06	'	'	'
2000 Plan [Member]	'	'	'	'	'	'
Capital Transaction (Textual)	'	'	'	'	'	'
Common stock, shares outstanding	'	63,000	'	63,000	'	'
2001 Plan [Member]	'	'	'	'	'	'
Capital Transaction (Textual)	'	'	'	'	'	'
Common stock, shares outstanding	'	718,000	'	718,000	'	'
2006 Plan [Member]	'	'	'	'	'	'
Capital Transaction (Textual)	'	'	'	'	'	'
Increase in common stock shares authorized under stock option plan	'	25,000,000	'	25,000,000	'	'
2006 Plan One [Member]	'	'	'	'	'	'
Capital Transaction (Textual)	'	'	'	'	'	'
Common stock, shares authorized	'	25,000,000	'	25,000,000	'	'
Shares Outstanding Under Stock Option Plan	'	19,969,000	'	'	'	'
Options converted with merger	'	14,061,000	'	'	'	'
Options outstanding under stock option plan	'	5,031,000	'	5,031,000	'	'
Period over which stock option is vested and expired	'	'Options vest over a period not greater than five years, and expire no later than ten years from the date of grant.	'	'	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	Dec. 31, 2012
Net Operating Loss and Research and Development Credit Carryforwards	'
Net operating loss	$38,655,000
Research and Development Tax Credits	560,000,000
2013 [Member]	'
Net Operating Loss and Research and Development Credit Carryforwards	'
Net operating loss	7,413,000,000
Research and Development Tax Credits	123,000,000
2018 - 2031 [Member]	'
Net Operating Loss and Research and Development Credit Carryforwards	'
Net operating loss	31,242,000,000
Research and Development Tax Credits	$437,000,000

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Difference between income taxes at statutory federal income tax rate	'	'
Income tax benefit at the federal statutory rate	($733,000)	($3,832,000)
Impairment of non-deductible tax goodwill	'	2,763,000
Expired net operating losses	2,386,000	1,580,000
Change in valuation allowance	-1,791,000	-896,000
Income from forgiveness of debt	'	-457,000
Difference in reporting basis between tax and accounting due to the Merger transaction	'	332,000
Expired R&D credit	267,000	'
Stock based compensation	4,000	287,000
Company's obligation paid by shareholder	'	234,000
State and local income tax, net of effect on federal taxes	-128,000	-101,000
Other	-5,000	90,000
Income Tax Benefit Continuing Operations	$0	$0

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Deferred tax asset	'	'
Net operating loss carryforward	$14,052,000	$15,568,000
Research and development credit carryforward	560,000	816,000
Other	400,000	400,000
Deferred Tax Assets, Gross	15,012,000	16,802,000
Valuation allowance	-15,012,000	-16,802,000
Deferred Tax Assets, Net	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Income Taxes (Textual)	'	'
Net operating loss carryforwards	$38,655,000	'
Research and Development Tax Credit	560,000	816,000
Net operating loss carryforwards State income tax	15,128,000	'
Federal tax rate	2.87%	'
Deferred Tax Assets	15,012,000	16,802,000
Valuation allowance	15,012,000	16,802,000
Operating loss carryforward expiration description	'Through 2027.	'
Decrease in valuation allowance	$1,791,000	'

Research_and_License_Agreement1

Research and License Agreements (Details)

12 Months Ended

50 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Apr. 30, 2012

Apr. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

USD ($)

USD ($)

USD ($)

University of Glasgow Agreement [Member]

University of Glasgow Agreement [Member]

University of Glasgow Agreement [Member]

University of Glasgow Agreement [Member]

MGH Agreement [Member]

Yissum Agreement [Member]

Dizerega Agreement [Member]

Dizerega Agreement [Member]

Former [Member]

USD ($)

GBP (£)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Research and License Agreements (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

Payment of royalty ranging on sales minimum (in percentage)

'

'

'

'

'

1.50%

'

10.00%

'

'

'

'

Payment of royalty ranging on sales Maximum (in percentage)

'

'

'

'

'

3.00%

'

20.00%

'

'

'

'

Additional payment of royalty ranging on sales (in percentage)

'

'

'

'

'

'

'

3.00%

'

'

'

'

Obligation of cumulative payment under license agreement term

'

'

'

'

'

$12,000,000

'

$15,000,000

'

'

'

'

Number of years for agreement termination from the date of the first commercial sale of a product

'

'

'

'

'

'

'15 years

'

'

'

'

'

Total expenses

2,124,000

11,792,000

15,334,000

'

'

691,000

474,000

'

'

'

'

'

Cost of extended research period

'

'

'

700,000

432,000

408,000

'

'

'

'

'

'

Extended research period

'

'

'

'Twelve-month period through March 2013

'Twelve-month period through March 2013

'

'

'

'

'

'

'

Expenses incurred on research program

'

'

'

'

'

'

'

'

40,000

'

'

'

Product sales

114,000

73,000

187,000

'

'

'

'

15,000,000

'

'

'

'

Common stock issued to affiliates

'

'

'

'

'

'

'

'

1,000,000

'

'

5,000,000

Fair value of common stock

'

'

'

'

'

'

'

'

350,000

'

'

'

Cash paid

'

'

'

'

'

'

'

'

150,000

'

'

'

Additional common stock, shares issued

'

'

'

'

'

'

'

'

4,000,000

'

'

'

Agreement liability

'

'

'

'

'

'

'

'

438,000

'

'

'

Net gain/loss

'

'

'

'

'

'

'

'

88,000

'

'

'

Escrow release amount

'

'

'

'

'

'

'

'

150,000

'

'

'

Description of period of agreement

'

'

'

'

'

'

'

'

'

'The agreement continues until the end of fifteen years from the date of the first commercial sale of such covered product in that country.

'

'

Royalty expense

'

'

'

'

'

'

'

'

'

$1,000

'

'

Percentage of royalty

'

'

'

'

'

'

'

'

'

'

1.00%

'

Commitments_and_Other_Matters_

Commitments and Other Matters (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	Individulas
Employment Agreement [Member]	'
Commitments and Other Matters (Textual)	'
Number of Individuals	1
Agreement expiry date	30-Sep-13
Agreement renewal period	'1 year
Cash severance benefits	$28,000
Annual salary obligation	110,000
Lease commitments [Member]	'
Commitments and Other Matters (Textual)	'
Rent expense under the operating lease	$7,200
Operating lease, description	'The Company has a one year operating lease commitment for office facilities space through June 2013.

Related_Parties_Details

Related Parties (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Mar. 31, 2011
Dr. Franklin [Member]	'	'
Related Party Transactions (Textual)	'	'
Payment of consulting fee	$10,000	'
Consulting fee before reduction	15,000	'
Breisgau BioVenures SA [Member]	'	'
Related Party Transactions (Textual)	'	'
Aggregate principal amount	'	1,357,000
Investment ownership percentage by investor	'	52.50%
Additional amount borrowed	$700,000	'
University of Glasgow [Member]	'	'
Related Party Transactions (Textual)	'	'
Investment ownership percentage by investor	9.50%	'
Dr. Shiels [Member]	'	'
Related Party Transactions (Textual)	'	'
Investment ownership percentage by investor	5.70%	'
Dr. Davies [Member]	'	'
Related Party Transactions (Textual)	'	'
Investment ownership percentage by investor	3.80%	'

Retirement_Plan_Details

Retirement Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Retirement Plan (Textual)	'	'
Company obligated matching contribution percentage of each employee's salary	100.00%	'
Deferral contributions rate of percentage of total compensation	4.00%	'
Deferral contributions amount of total compensation	$245,000	'
Amount of matching contribution retirement plan	$4,400	$1,800

Nature_of_Business_Details

Nature of Business (Details) (USD $)	12 Months Ended		50 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Revenue	'	'	'
Revenues	$114	$73	$187
United States [Member]	'	'	'
Revenue	'	'	'
Revenues	13	7	'
Brazil [Member]	'	'	'
Revenue	'	'	'
Revenues	17	'	'
Colombia [Member]	'	'	'
Revenue	'	'	'
Revenues	15	'	'
Italy [Member]	'	'	'
Revenue	'	'	'
Revenues	2	5	'
Czech Republic [Member]	'	'	'
Revenue	'	'	'
Revenues	15	5	'
Hong Kong [Member]	'	'	'
Revenue	'	'	'
Revenues	37	54	'
Russia [Member]	'	'	'
Revenue	'	'	'
Revenues	15	'	'
Other Countries [Member]	'	'	'
Revenue	'	'	'
Revenues	'	$2	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	Dec. 31, 2012
Subsequent Events (Textual)	'
Aggregate borrowed amount	$305,000